Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis (MS) wherein T helper (Th) 17 cells are the major pathogenic players orchestrating demyelination of axons. Recently in PNAS, Poppensieker et al. (1) documented a key role on the requirement of CC chemokine receptor 4 (CCR4) in EAE. The authors reported that CCR4 is required for GM-CSF-dependent IL-23 secretion by dendritic cells (DCs) in the CNS and for the maintenance of Th17 cells and the development of EAE. The results thus indicate that CCR4 is a potential therapeutic target in EAE, and eventually MS.
Therapeutic strategies to target DC-specific CCR4
are not yet available. However, several functionally potent small molecule antagonists to CCR4 in general, irrespective of its expression on cell types, have been identified (2, 3) . Therefore, we explored the therapeutic utility of antagonizing CCR4 in EAE.
We induced EAE in C57BL/6 mice in three different groups by injecting myelin oligodendrocyte glycoprotein (MOG (2, 4) . Mice in the control group developed clinical signs from d8 onwards, reaching a mean maximal score of 2.5 on d20 (Fig. 1A) . However, the group of mice with EAE that were treated with CCR4 antagonists did not show any significant reduction in the clinical score, and the disease pattern remained the same as that of controls.
To explore whether prophylactic use of CCR4 antagonists would ameliorate clinical signs of EAE, a group of mice were injected with CCR4 antagonists from d0 to d4. In contrast to therapeutic use of CCR4 antagonists, mice that received prophylactic injections of CCR4 antagonists showed an exaggerated disease pattern with the clinical scores close to statistical significance compared with control mice (P = 0.07) (Fig. 1A) . Further, we did not observe any significant differences in the mean maximal score of EAE in controls and the two treated groups (Fig. 1B) . Also, the incidence of EAE was the same with or without CCR4 antagonism (Fig. 1C) .
These results suggest that antagonizing CCR4 in general without cell specificity has no beneficial effect in EAE. The possible reason could be that CCR4 is also expressed by CD4 + CD25 + FoxP3 + regulatory T cells (Tregs 
